Combining a Novel Affibody-Conjugated Prodrug System with Radiotherapy to Enhance Antitumor Effects ― Targeting Her2-Positive Tumors

Project title

合併新型標靶載體前驅藥融合蛋白與放射線治療以提升抑癌效果—以表皮生長因子受體第二型腫瘤為標的

Internal ID

NSTC112-2314-B002-248-MY3

Principal Investigator

Start Date

August 1, 2023

End Date

July 31, 2024

Investigators

Organizations

Partner Organizations

National Science and Technology Council